[ad_1]
Harvard Bioscience, Inc. (NASDAQ: HBIO) shares were flat Thursday, on the announcement that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 – 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ implantable telemetry platform, and the VivaMARS™ activity monitoring system.
The Company will exhibit its organoid-centric mesh Microelectrode Array platform, which continues to gain traction among the scientific and therapy development communities. Unlike traditional technologies, the new Mesh MEA organoid platform captures electrophysiology signals from inside the organoid in real time, providing researchers with exciting new insights into complex neural dynamics and brain disorders.
The Mesh MEA platform is currently being evaluated at select test sites for neurological and cardiac research in addition to safety pharmacology and toxicology applications. The Company has also begun limited quantity shipments to early adopters, with full production expected in the first half of 2025.
The Company will also be showcasing its SoHo implantable real-time telemetry solution for small animal models. Integrated with the Company’s industry-leading Ponemah™ data management platform, the SoHo telemetry system allows users to collect, manage, analyze and report findings from multiple concurrent small animal models in a shared housing environment, ensuring precision and reliability in behavioral and neurophysiological experiments
HBIO shares took on but 1.5 cents to $2.57.
[ad_2]
Source link